BofA Securities Downgrades BioXcel Therapeutics to Underperform From Buy, Adjusts Price Target to $0.25 From $7
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1650 USD | -11.58% |
|
-96.84% | -97.24% |
02-06 | BioXcel to Implement Reverse Stock Split; Shares Fall | MT |
02-05 | BioXcel Therapeutics Provides Clinical and Business Update | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration